Association between insulin-like growth factor-1 receptor (IGF1R) negativity and poor prognosis in a cohort of women with primary breast cancer

Table 1 Cytoplasmic intensity of IGF1R expression in relation to tumor and patient characteristics for Cohort I (N = 264) and Cohort II (N = 206)

	Cohort I	% of patients with different expression levels					Cohort II	% of patients with different expression levels
	N	Neg	Weak	Moderate	Strong	p-value	N	Neg	Weak	Moderate	Strong	p-value
Total	264	11	32	43	14		206	2	30	58	10
Age
Median age	264	63^a	61^a	63^a	60^a	0.34^b	206	45^a	46^a	47^a	47^a	0.026^b
Menopausal status
Pre	55	7	29	45	18	0.15^c	n/a
Post	209	12	33	43	12
Tumor size
0 – 20 mm	78	8	35	50	8	0.83^c	156	3	30	58	10	0.74^c
>20 mm	186	13	31	40	16		50	2	28	60	10
Node status
N0	86	12	35	41	13	0.52^c	n/a
N+	178	11	30	44	14
NHG
1 – 2	186	8	32	45	15	0.086^c	138	1	29	62	9	0.39^c
3	75	19	31	39	12		66	6	32	50	12
Missing	3						2
ER
Positive	174	3	29	49	18	<0.001^c	139	1	27	63	9	0.32^c
Negative	80	29	38	29	5		67	4	34	49	12
Missing	10						0
PgR
Positive	133	2	29	52	17	<0.001^c	149	1	28	63	7	0.66^c
Negative	121	21	34	33	12		57	5	33	46	16
Missing	10						0
Ki67
Low	162	8	33	43	16	0.095^c	125	2	32	59	7	0.33^c
High	99	17	29	43	10		61	3	28	52	16
Missing	3						20
HER2
Negative	199	9	32	44	15	0.042^c	171	1	29	60	9	0.027^c
Positive	33	21	33	39	6		22	14	41	36	9
Missing	32						13
St Gallen subgroups ^d
Luminal A-like	72	4	32	46	18	<0.001^e	92	0	27	64	9	0.24^e
Luminal B-like	80	4	26	51	19		32	3	31	53	13
Triple-negative	42	26	43	26	5		32	3	41	41	16
HER2+ (non-luminal)	18	39	33	22	6		8	25	38	25	13
Missing	52						42

Abbreviations: ER = Estrogen receptor, PgR = Progesterone receptor, HER2 = Human epidermal growth factor receptor 2, NHG = Histological grade according to Elston and Ellis [35], n/a = Not applicable.
^aMedian age in the different groups.
^bSpearman’s rank-correlation.
^cMann–Whitney test.
^dSee (34) for complete definition of St Gallen subgroups.
^eKruskal-Wallis test.

ISSN: 1471-2407